| Use of physiologically based pharmacokinetic (PBPK) modeling for predicting drug-food interactions: an industry perspective AE Riedmaier, K DeMent, J Huckle, P Bransford, C Stillhart, R Lloyd, ... The AAPS journal 22, 1-15, 2020 | 81 | 2020 |
| Nanoparticle biodistribution coefficients: A quantitative approach for understanding the tissue distribution of nanoparticles M Kumar, P Kulkarni, S Liu, N Chemuturi, DK Shah Advanced Drug Delivery Reviews 194, 114708, 2023 | 72 | 2023 |
| Transferosomes: an emerging tool for transdermal drug delivery PR Kulkarni, JD Yadav, KA Vaidya, PP Gandhi International journal of pharmaceutical sciences and research 2 (4), 735, 2011 | 52 | 2011 |
| Intracellular unbound atorvastatin concentrations in the presence of metabolism and transport P Kulkarni, K Korzekwa, S Nagar Journal of Pharmacology and Experimental Therapeutics 359 (1), 26-36, 2016 | 17 | 2016 |
| Prediction of drug-induced kidney injury in drug discovery P Kulkarni Drug Metabolism Reviews, 2021 | 11 | 2021 |
| P-glycoprotein substrate assessment in drug discovery: Application of modeling to bridge differential protein expression across in vitro tools N Li, P Kulkarni, A Badrinarayanan, A Kefelegn, R Manoukian, X Li, ... Journal of Pharmaceutical Sciences 110 (1), 325-337, 2021 | 8 | 2021 |
| Streamlining food effect assessment—are repeated food effect studies needed? An IQ analysis F Kesisoglou, S Basu, T Belubbi, P Bransford, J Chung, S Dodd, M Dolton, ... The AAPS Journal 25 (4), 60, 2023 | 6 | 2023 |
| Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a … A Trivedi, W Sohn, P Kulkarni, P Jafarinasabian, H Zhang, M Spring, ... Clinical and Translational Science 14 (6), 2510-2520, 2021 | 6 | 2021 |
| A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats P Kulkarni, K Korzekwa, S Nagar Xenobiotica 50 (5), 536-544, 2020 | 5 | 2020 |
| Dissecting parameters contributing to the underprediction of aldehyde oxidase-mediated metabolic clearance of drugs S Subash, DK Singh, DS Ahire, SC Khojasteh, BP Murray, MA Zientek, ... Drug Metabolism and Disposition 51 (10), 1362-1371, 2023 | 3 | 2023 |
| Prediction of drug clearance from enzyme and transporter kinetics PR Kulkarni, AS Youssef, AA Argikar Enzyme Kinetics in Drug Metabolism: Fundamentals and Applications, 369-417, 2021 | 3 | 2021 |
| Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates N Izat, J Bolleddula, P Carione, L Huertas Valentin, RS Jones, P Kulkarni, ... CPT: Pharmacometrics & Systems Pharmacology, 2024 | | 2024 |
| Ontogeny of Human Liver Aldehyde Oxidase: Developmental Changes and Implications for Drug Metabolism S Subash, DK Singh, D Ahire, SC Khojasteh, BP Murray, MA Zientek, ... Molecular pharmaceutics 21 (6), 2740-2750, 2024 | | 2024 |
| In vitro uptake of an MC3 lipid nanoparticle formulation by mice, non-human primate, and human hepatocytes and Kupffer cells P Sandoval, J Idowu, N Chemuturi, P Kulkarni, M McCoy Drug Metabolism and Pharmacokinetics 55, 100914, 2024 | | 2024 |
| Correction to: Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective AE Riedmaier, K DeMent, J Huckle, P Bransford, C Stillhart, R Lloyd, ... The AAPS Journal 23 (1), 6, 2020 | | 2020 |
| Intracellular Unbound Concentrations of Atorvastatin and Bosentan: Prediction Using Modeling and Simulation, and Effect of Metabolism and Transport PR Kulkarni Temple University, 2017 | | 2017 |
